Regeneron posts blockbuster Q3 results, prompting analysts to lift price targets
+5 new sources since this summary was written
Regeneron Pharmaceuticals reported third‑quarter 2026 earnings that far exceeded expectations, with adjusted earnings of $20.07 per share and revenue of $5.12 billion. The surge was driven by record collaboration revenue of $2.7 billion from its partnership with Sanofi on Dupixent and strong sales of Eylea HD. Analysts at Guggenheim and BofA Securities raised their price targets to $1,100 and $1,030 respectively, citing the impressive performance. The company also announced a $1 billion upfront payment from Sanofi to be recorded in the fourth quarter.
Why it matters
Guggenheim’s note says the higher target implies an 18.5% upside from the recent close, while BofA Securities notes an 11% upside, suggesting further upside potential for investors. The upcoming $1 billion Sanofi payment will boost fourth‑quarter revenue, potentially supporting the stock’s momentum.
Key facts
- 1Adjusted earnings were $20.07 per share, up 70% from the prior year. ibtimes.com.au
- 2Revenue reached $5.12 billion, a 36% increase year over year. ibtimes.com.au
- 3Collaboration revenue from Sanofi totaled $2.7 billion, up 68% YoY. ibtimes.com.au
- 4The stock rose 13.33% to close at $927.89, its 52‑week high. ibtimes.com.au
- 5Guggenheim raised its price target to $1,100 from $1,030. investing.com
- 6BofA Securities increased its price target to $1,030 from $908. tradingview.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.